Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4602 in HER2-expressing/mutated solid tumors
NCT06560138Phase 1Withdrawn
- Sponsor
- Atridia Pty Ltd
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4602 in solid tumor, sponsored by Atridia Pty Ltd. Primary endpoint: Recommended Phase 2 Dose up to 1 year. Planned start Mar 2025; status: withdrawn.
02
Drugs
SHR-4602
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06560138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560138.